ArticleJournal of cardiothoracic surgery2026
Senhance-assisted thoracoscopic surgery for mediastinal tumor.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Minimally invasive surgery has become the standard approach in many fields, including thoracic surgery. Robot-assisted thoracoscopic surgery (RATS) has been increasingly introduced over the past two decades. The Senhance™ surgical system (Asensus Surgical, Inc.) was developed as a next-generation robotic platform. At our institution, nine thoracic surgical procedures for mediastinal tumor were performed at our institution using the Senhance™ surgical system. The procedures included six thymomas, two thymic cysts, and one pericardial cyst. Operative time ranged from 146 to 285 min (median, 182 min). The duration of Senhance™ utilization ranged from 30 to 138 min (median, 51 min). Estimated blood loss ranged from 22 to 100 mL (median, 30 mL). One patient developed a postoperative subcutaneous hematoma at the port site, requiring surgical evacuation the following day, while all other postoperative courses were uneventful. These findings suggest that the application of the Senhance system for mediastinal tumor resection is feasible and associated with an acceptable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.